Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

The FDA has approved Vertex’s suzetrigine (Journavx), an oral inhibitor of voltage-gated sodium channel 1.8 (Na V 1.8), for the treatment of moderate to severe acute pain. The decision provides ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new evidence review suggests. These patients might experience loss of balance and coordination ...

The pain is usually peripheral to the entrapment point, though retrograde distribution may occur. Tenderness is present at the entrapment point, where properly applied pressure may reproduce the ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

Peripheral nerves are the nerves that travel from the spine and the brain to the other areas of the body such as the hands or the feet. Gluten neuropathy may result in symptoms such as numbness, ...

The drug is highly selective for NaV1.8, a voltage-gated sodium channel selectively expressed in peripheral pain-sensing neurons. Unlike opioids, suzetrigine blocks pain signals found only in the ...